Eupraxia Pharmaceuticals (NASDAQ: EPRX) is behaving less like a sleepy small-cap from Victoria and more like a company auditioning for prime time in the EoE treatment lineup. With six‑month symptom data from its RESOLVE trial now in hand and a fortified balance sheet coming out of 2025, the pieces are lining up for a pivotal second half of 2026.
Six Months In: Symptoms Don’t Just Improve, They Keep Improving
The latest RESOLVE Part A update focuses on the two highest-dose cohorts of EP‑104GI, Eupraxia’s extended‑release fluticasone injected directly into the esophageal wall. In the highest-dose Cohort 9 (20 x 8 mg), patients achieved an average 4‑point reduction on the Straumann Dysphagia Index (SDI) at 24 weeks; clinical remission is defined as a 3‑point reduction, so the bar wasn’t just cleared, it was given some air.
Pooling cohorts with at least 12 injections (cohorts 4–9), Eupraxia reports clinical remission rates of 59% at 12 weeks, 76% at 24 weeks, and 67% at 52 weeks after a single treatment – an unusual durability profile in a disease accustomed to weekly therapies. i.e Sanofi’s Dupixent that they reported they enjoyed approximately 17.7 billion dollars in sales over the last 12 months. The fact that symptom benefit appears strongest at 24 weeks underscores what management has hinted at all along: EP‑104GI is designed as a “long game” asset where efficacy builds, not fades, over time.
Cleaning Up The Delivery, Clarifying The Signal
Not all high‑dose cohorts are created equal, and Eupraxia’s delivery hardware has now had its own “version upgrade.” Earlier data from a 6 mg per‑site cohort were clouded by catheter clogging, prompting the company to re‑run that dose level with a larger 19‑gauge catheter that is now standard going forward. In this “8b” refresh, patients saw an average SDI reduction of roughly 3.8 points at 12 weeks, compared with a negligible change in the original 6 mg cohort, neatly tying the earlier aberration to under‑delivery rather than under‑performance.
Taken together, the 6 mg and 8 mg cohorts now show a consistent dose‑response in both symptom relief and histologic improvement, with several patients maintaining clinical remission out to one year after a single administration. For investors, the message is straightforward: the doses now being used in the randomized Part B study are the same ones generating the cleanest and most compelling data.
Safety Profile: Long Follow-Up, Short Adverse Event List
For any steroid‑based approach, safety is where the skepticism usually gathers – yet that’s precisely where EP‑104GI has been the least dramatic. Across 31 treated patients and more than 220 patient‑months of follow‑up, Eupraxia reports no serious adverse events and, notably, none of the usual steroid‑related suspects such as candidiasis, adrenal insufficiency or glucose dysregulation, even in a diabetic patient.
The highest dose tested, 8 mg per site, has been described as well tolerated, with no new safety signals emerging as patients move out to the six‑ and twelve‑month marks. In an era where black‑box warnings can wipe out years of R&D value in a single line of fine print, the absence of late‑breaking safety surprises is quietly becoming one of EP‑104GI’s more valuable attributes.
From Pivotal 2025 To Pivotal 2026: The Financial Runway
The six‑month data would matter less if Eupraxia were racing the clock on its cash balance; instead, 2025’s “pivotal year” has given the company room to maneuver. The firm ended 2025 with roughly 80.5 million in cash, up sharply from 33.1 million a year earlier, thanks in part to recent financings explicitly aimed at driving EP‑104GI through key mid‑stage milestones.
Management now guides that existing cash plus expected warrant exercises should fund operations into the second half of 2028, comfortably beyond the Phase 2b readout in the second half of 2026 and into the next wave of clinical programs. For a clinical‑stage company, that kind of runway allows the science – not the ATM – to dictate the news flow.
Eye On The Next Catalyst: Phase 2b In 2H26
All of this work in Part A is effectively a dress rehearsal for the main event: the placebo‑controlled Phase 2b portion of RESOLVE. The ongoing Part B is enrolling 120 patients randomized to placebo, a 20 x 6 mg arm, and a 20 x 8 mg arm, with a six‑month unblinding planned and top‑line data expected in the second half of 2026.
With Part A already showing remission rates in the mid‑double digits and six‑month SDI reductions that exceed the clinical remission threshold, the bar for Phase 2b is now less about “does it work?” and more about “how competitive can it be versus weekly biologics in a commercial setting?” If EP‑104GI can deliver once‑yearly or near‑annual dosing with a profile that stacks up respectably against current leaders, EoE could evolve from a niche opportunity to the first leg of a broader franchise.
Beyond EoE: A Platform Quietly Building
EP‑104GI may be grabbing the headlines, but Eupraxia’s Diffusphere technology is the engine behind the story. The same microsphere‑based platform has already carried EP‑104IAR through a Phase 2b trial in knee osteoarthritis, where the program met its primary endpoint and three of four secondary endpoints, suggesting that “long‑acting local steroid delivery” is not a one‑off idea.
Management has pointed to additional gastrointestinal and inflammatory joint indications, as well as oncology‑focused candidates, as logical extensions; analysts, for now, have tended to model only a subset of that potential, leaving pipeline expansion as unmodeled upside. In other words, it is believed that EP‑104GI is not just a product candidate – it is a proof‑of‑concept for a platform that may ultimately outgrow its first indication.
Analyst Playbook: Three Bulls, Three Targets
On the Street, three firms are now effectively rowing in the same direction on Eupraxia (NASDAQ: EPRX), each with a bullish stance and double‑digit upside targets. Craig‑Hallum’s Albert Lowe reiterates a Buy rating with a 12‑month price target of 14 dollars, highlighting high rates of clinical remission at go‑forward Phase IIb doses and framing EP‑104GI as a potential “best in disease” therapy in eosinophilic esophagitis. Raymond James, led by Martin Auster, MD, keeps a Strong Buy (SB1) rating and an 18 dollar target, arguing that the latest high‑dose RESOLVE Part A data are “supportive and incremental,” reinforce a clean safety profile, and leave the program well‑positioned heading into placebo‑controlled Part B data in 2H26.
Cantor Fitzgerald’s Kristen Kluska rounds out the trio with an Overweight rating and the most aggressive target at 19 dollars, based on a probability‑adjusted DCF that assumes EP‑104GI can support a multi‑billion‑dollar opportunity if upcoming Phase 2b data cooperate. Her team calls EPRX a “must own” ahead of the 3Q26 readout and notes that every 10‑percentage‑point increase in probability of success adds roughly six dollars to their DCF‑derived valuation, underscoring just how much leverage sits in the data. Put together, the three firms are less debating direction than velocity: all see material upside from here; the only real disagreement is how quickly the market decides to price it in. *** Contact these three firms to gain access to the complete reports. ***
The Market’s “Must-Watch” List Just Got Longer
For many well-informed biotech investors, Eupraxia’s (NASDAQ: EPRX) latest update checks off several key boxes: a clear dose‑response, durable remission out to one year, an increasingly well‑defined safety profile, and enough capital to see the program through a critical data readout. The sample sizes in Part A remain small, and Phase 2b will need to confirm these encouraging trends in a larger, placebo‑controlled setting, but the risk‑reward profile is shifting from “speculative idea” toward “under‑followed late‑stage asset.”
In a market where many EoE therapies ask patients for unwavering weekly loyalty, EP‑104GI is offering something different: a shot at durable control with a treatment cadence closer to a calendar reminder than a lifestyle. For a growing segment of healthcare investors, that may be reason enough to keep Eupraxia on the screen between now and the Phase 2b unveiling in the second half of 2026.
The Sources
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in the EP-104GI RESOLVE Trial – Finance Yahoo
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-six-month-110000698.html - Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results – Finance Yahoo
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-fourth-quarter-010300777.html - Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in the EP-104GI RESOLVE Trial – GlobeNewswire
https://www.globenewswire.com/news-release/2026/03/13/3255235/0/en/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-highest-dose-cohort-in-the-ep-104gi-resolve-trial.html - Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results – GlobeNewswire
https://www.globenewswire.com/news-release/2026/03/13/3255235/0/en/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update.html - Stock Titan summary of Eupraxia 24-week EoE trial data
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-bs820zazcdnz.html - TipRanks news: Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI
https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-posts-strong-six-month-eoe-data-for-ep-104gi-as-resolve-trial-advances - ClinicalTrials.gov – EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE, NCT05608681)
https://clinicaltrials.gov/study/NCT05608681 - Eupraxia Pharmaceuticals corporate website
https://eupraxiapharma.com - Cantor Fitzgerald March 17, 2026 Research Update on Eupraxia (EP-104GI Six-Month High Dose Data)
- Raymond James March 17, 2026 Research Update on Eupraxia (Supportive Incremental Data Update from RESOLVE Part A)
- Craig-Hallum March 17, 2026 Company Note on Eupraxia (High Rates of Clinical Remission at Go-Forward Doses)
